Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103661 | 0.97 | — | — | |
| SCHEMBL29366238 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL5387641 | 0.94 | — | — | |
| SCHEMBL4073143 | 0.94 | — | — | |
| SCHEMBL28236324 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL28532112 | 0.94 | ALDH1A1 (0.50) | — | |
| Calcium SCHEMBL38655972 | 0.94 | — | — | |
| SCHEMBL28385351 | 0.94 | — | — | |
| Formaldehyde SCHEMBL27789023 | 0.90 | L3MBTL1 (0.46) | — | |
| SCHEMBL28388991 | 0.87 | L3MBTL1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109575086-A | Forcipated phosphine ligand iridium metal catalyst and preparation method and application thereof | 中国科学院理化技术研究所 | 2019-04-05 | — | — | CN | claimed |
| EP-0957903-A4 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS INC (US) | 2002-10-09 | — | — | EP | claimed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | claimed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| EP-0957903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Codon Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | claimed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | claimed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | claimed |
| WO-1998011882-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | claimed |
| CN-109575086-A | Forcipated phosphine ligand iridium metal catalyst and preparation method and application thereof | 中国科学院理化技术研究所 | 2019-04-05 | — | — | CN | disclosed |
| US-7250157-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060120976-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2006-06-08 | — | — | US | disclosed |
| US-6955804-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DEMATICS (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040067209-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS | 2004-04-08 | — | — | US | disclosed |
| US-6623724-B2 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2003-09-23 | — | — | US | disclosed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | disclosed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| US-6294585-B1 | ADMINISTERING NORBORNANE DIOL/TRIOL OR NORBORNENE DIOL/TRIOL DERIVATIVES FOR INCREASING DIFFERENTIATION OF MAMMALIAN NEURONAL CELLS | APPLIED GENETICS INCORPORATED DERMATICS | 2001-09-25 | — | — | US | disclosed |
| EP-0957903-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | Codon Pharmaceuticals, Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| US-5990177-A | CYCLIC AND ACYCLIC MONO-, DI- AND TRIALCOHOLS AS STIMULANTS TO TREAT DISEASES MEDIATED BY DEFICIENCIES IN THE NITRIC OXIDE/CYCLIC GUANOSINE MONOPHOSPHATE/PROTEIN KINASE G SIGNAL TRANSDUCTION PATHWAY; CARDIOVASCULAR; SKIN; NERVOUS SYSTEM | CODON PHARMACEUTICALS, INC. (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1998011882-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-03-26 | — | — | WO | disclosed |